Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Neoplasms: early-phase trial registry
9 of 24 indexed Lung Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 9 currently recruiting · #686 of 28,707 conditions by registered trial count
Lung Neoplasms: 24 US clinical trials tracked, 9 recruiting.
Lung Neoplasms is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Syndax Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition lung-neoplasms
OPEN 9 | RECR 38% | LATE 3 | EARLY 13 | RANK #686 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Lung Neoplasms lists 9 open slots (38% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Neoplasms is recruiting below its size-band peers.
9 of 24 indexed trials (37.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lung Neoplasms trials is spread across many organizations.
Syndax Pharmaceuticals accounts for 2 of 24 trials (8.3%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Lung Neoplasms trials plan to enrol fewer than 100 people.
Median target enrolment is 80 among the 23 trials that report a genuine target (sentinel values excluded). 14 of those (60.9%) plan for fewer than 100 participants.
-
Lung Neoplasms research is mostly interventional.
19 interventional and 5 observational studies make up this index (79.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Real World Registry for Use of the Ion Endoluminal System
Intuitive Surgical
NCT06004440
Specimen Banking From Patients With Lung Cancer
University of Colorado, Denver
NCT01585675
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
Wake Forest University Health Sciences
NCT04577599
TELESCOPE- TELEhealth Shared Decision-making COaching
Rutgers, The State University of New Jersey
NCT05491213
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
University of Colorado, Denver
NCT01580982
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
NCT06885697
TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics
Rutgers, The State University of New Jersey
NCT07165691
Circulating Tumor Cells (CTC) in Lung Cancer
Shadia Jalal
NCT02630615
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Brown University
NCT06974604
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Merck Sharp & Dohme
NCT04380636
A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
Proton Collaborative Group
NCT01770418
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT06237881
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme
NCT04738487
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
On Target Laboratories
NCT04241315
Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity
University of Rochester
NCT00178230
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Amgen
NCT00413283
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
NewLink Genetics Corporation
NCT00073398
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00001499
Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00063219
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02897778
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02909452
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics
NCT00120939
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
University of California, San Diego
NCT01114958
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
Pfizer
NCT00034957
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 5 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Neoplasms page
24 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Lung Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Syndax Pharmaceuticals sponsors the most Lung Neoplasms trials on record, review their full trial history before evaluating a specific study. See Syndax Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Neoplasms condition card totals 24 registered trials; most-linked intervention TELESCOPE, Remote Decision Coaching with Navigation Intervention; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.